一名接受达卡巴嗪（DTIC）治疗恶性黑色素瘤的患者出现肝衰竭。
Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.
作者信息
Frosch P J, Czarnetzki B M, Macher E, Grundmann E, Gottschalk I
出版信息
J Cancer Res Clin Oncol. 1979;95(3):281-6. doi: 10.1007/BF00410649.
Abstract
A 55-year-old white woman received chemotherapy with DTIC after surgery for malignant melanoma (stage I, SSM IV, depth of invasion 12 mm). She died suddenly during the second treatment cycle. Autopsy revealed massive necrosis of the liver and thrombosis of the hepatic veins. The cause of the fatal outcome is attributed to the adverse toxic effects of DTIC.
摘要
一名55岁的白人女性在接受恶性黑色素瘤手术（I期，浅表扩散性黑色素瘤IV型，浸润深度12毫米）后接受了达卡巴嗪化疗。她在第二个治疗周期中突然死亡。尸检显示肝脏大面积坏死和肝静脉血栓形成。致命结果的原因归因于达卡巴嗪的不良毒性作用。
相似文献
1
Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.
J Cancer Res Clin Oncol. 1979;95(3):281-6. doi: 10.1007/BF00410649.
2
[Dacarbazine in malignant melanoma. Rare, severe side-effect: Budd-Chiari-syndrome (author's transl)].
Z Hautkr. 1982 Jul 1;57(13):971-80.
3
[Budd-Chiari syndrome following dacarbazine therapy of malignant melanoma--an avoidable complication?].
Z Hautkr. 1985 Jun 15;60(12):961-72.
4
Fatal hepatic vascular toxicity of DTIC. Is it really a rare event?
Cancer. 1988 May 15;61(10):1988-91. doi: 10.1002/1097-0142(19880515)61:10<1988::aid-cncr2820611010>3.0.co;2-5.
5
Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment.
Cancer Treat Rep. 1983 Sep;67(9):779-84.
6
Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.
J Surg Oncol. 1984 Dec;27(4):268-70. doi: 10.1002/jso.2930270415.
7
Hepatic veno-occlusive disease due to DTIC.
Cancer. 1980 May 15;45(10):2670-4. doi: 10.1002/1097-0142(19800515)45:10<2670::aid-cncr2820451031>3.0.co;2-l.
8
[Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)].
Klin Wochenschr. 1981 Mar 2;59(5):229-36. doi: 10.1007/BF01476580.
9
Allergy-induced hepatic toxicity associated with dacarbazine.
Cancer Treat Rep. 1987 Feb;71(2):219-20.
10
[Budd-Chiari syndrome during treatment with dacarbazine (DTIC) (author's transl)].
Dtsch Med Wochenschr. 1980 Feb 15;105(7):230-3. doi: 10.1055/s-2008-1070640.
引用本文的文献
1
Current status and perspectives in immunotherapy for metastatic melanoma.
Oncotarget. 2018 Jan 3;9(15):12452-12470. doi: 10.18632/oncotarget.23746. eCollection 2018 Feb 23.
2
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
Cancer Chemother Pharmacol. 2015 Nov;76(5):969-75. doi: 10.1007/s00280-015-2870-0. Epub 2015 Sep 25.
3
A single-center experience in radioembolization as salvage therapy of hepatic metastases of uveal melanoma.
Acta Radiol Open. 2015 Apr 6;4(4):2047981615570417. doi: 10.1177/2047981615570417. eCollection 2015 Apr.
4
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
Ann N Y Acad Sci. 2013 Jul;1291(1):1-13. doi: 10.1111/nyas.12180. Epub 2013 Jun 17.
5
How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma.
Ann Oncol. 2012 Sep;23 Suppl 8(Suppl 8):viii15-21. doi: 10.1093/annonc/mds258.
6
A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.
Invest New Drugs. 1993 May-Aug;11(2-3):169-79. doi: 10.1007/BF00874151.
7
[Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)].
Klin Wochenschr. 1981 Mar 2;59(5):229-36. doi: 10.1007/BF01476580.
8
Drug effects on the liver. An updated tabular compilation of drugs and drug-related hepatic diseases.
Dig Dis Sci. 1983 Jul;28(7):651-66. doi: 10.1007/BF01299927.
9
DTIC (dacarbazine)-induced hepatic damage. Possible pathogenesis and prevention.
Arch Dermatol Res. 1981;270(3):375-6. doi: 10.1007/BF00403944.
10
Clinical management of cytotoxic drug overdose.
Med Toxicol Adverse Drug Exp. 1988 Jul-Aug;3(4):253-63. doi: 10.1007/BF03259938.
本文引用的文献
1
N-demethylation the antineoplastic agent4(5)-(3,3-dimethyl-1-triazeno)imidazole-5(4)-carboxamide by rats and man.
Cancer Res. 1970 Jan;30(1):147-50.
2
Combination phase 1-II study of imidazole carboxamide (NCS45388).
Oncology. 1972;26(2):310-6. doi: 10.1159/000224680.
3
Studies of the mechanism of action of the antitumor agent 5(4)-(3,3-dimethyl-1-triazeno) imidazole-4(5)-carboxamide in Bacillus subtilis.
Biochem Pharmacol. 1970 Mar;19(3):911-9. doi: 10.1016/0006-2952(70)90254-6.
4
Chemotherapy of malignant melanoma.
Cancer. 1972 Dec;30(6):1604-15. doi: 10.1002/1097-0142(197212)30:6<1604::aid-cncr2820300629>3.0.co;2-5.
5
Mechanism of action and pharmacology studies with DTIC (NSC-45388).
Cancer Treat Rep. 1976 Feb;60(2):149-52.
6
Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases.
Ann Intern Med. 1976 Nov;85(5):578-82. doi: 10.7326/0003-4819-85-5-578.
7
Phase I evaluation of DTIC (NSC-45388) and other studies in malignant melanoma in the Central Oncology Group.
Cancer Treat Rep. 1976 Feb;60(2):183-7.
8
Results with methyl-CCNU and DTIC in metastatic melanoma.
Cancer. 1977 Sep;40(3):1010-5. doi: 10.1002/1097-0142(197709)40:3<1010::aid-cncr2820400308>3.0.co;2-c.
9
Hepatic-vein thrombosis after chemotherapy for histiocytoma.
Ann Intern Med. 1978 Apr;88(4):575-6. doi: 10.7326/0003-4819-88-4-575_2.
10
Photodegradation of dacarbazine.
Lancet. 1978 Sep 23;2(8091):681. doi: 10.1016/s0140-6736(78)92794-0.
Zotero 插件